Abstract: The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based on the identification of cardiotrophin-1 gene amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis. Accordingly, the cardiotrophin-1 polypeptide encoded by the amplified gene is believed to be a useful target for the diagnosis and/or treatment (including prevention) of certain cancers, and may act as a predictor of the prognosis of tumor treatment.

Abstract: The present invention is directed to novel polypeptides having sequence similarity to Stra6, a murine retinoic acid responsive protein, and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.

Abstract: The present invention is directed to novel polypeptides having sequence similarity to Stra6, a murine retinoic acid responsive protein, and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The invention concerns the identification of tumor antigens the expression of which is selectively upregulated by retinoid treatment. The invention further concerns improved methods of cancer treatment and, in particular, methods enhancing the efficacy of the treatment of cancers characterized by aberrant Wnt signaling by administration of retinoic acid or other retinoids.

Abstract: A member of the guanylate-binding protein family, designated GBP-4, is provided. Also provided are isolated nucleic acid encoding GBP-4, vectors and host cells containing such nucleic acid molecule, and a method for producing the GBP-4 recombinantly.

Abstract: Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.

Abstract: A member of the guanylate-binding protein family, designated GBP-4, is provided. Also provided are isolated nucleic acid encoding GBP-4, vectors and host cells containing such nucleic acid molecule, and a method for producing the GBP-4 recombinantly.

Abstract: The present invention provides novel polypeptides, termed FCTRX polypeptides, as well as polynucleotides encoding FCTRX polypeptides and antibodies that immunospecifically bind to an FCTRX or a derivative, variant, mutant, or fragment of an FCTRX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the FCTRX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.

Abstract: The present invention provides novel polypeptides, termed FCTRX polypeptides, as well as polynucleotides encoding FCTRX polypeptides and antibodies that immunospecifically bind to an FCTRX or a derivative, variant, mutant, or fragment of an FCTRX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the FCTRX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.

Abstract: An isolated polypeptide comprising an amino acid sequence having at least 80% sequence identity to the sequence SEQ ID NOS:2, 4, 6 or 8, polynucleotides encoding these peptides, and antibodies to the polypeptides are useful in treating cancers.

Abstract: A transgenic bacterial host cell that can be used as a screen for novel antibiotics and herbicides is provided. The genome of the transgenic bacterial host cell comprises disruptions in a first endogenous gene in the MEP pathway) and a transgene that functionally replaces the disrupted first gene. In other embodiments, the genome comprises a disruption in a first endogenous gene in the MEP pathway and a second endogenous gene which is located downstream of the first gene in the MEP pathway. A transgene that functionally replaces the disrupted downstream gene is cloned into the host cell. A mini operon containing the essential genes for the MVA pathway may also be cloned into the host cell. The transgenic host cell may be used in a method for screening compounds for antibiotic and herbicidal properties. The agents determined by the screening method may be used to kill bacteria or plants.

Abstract: The invention concerns composititions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based on the identification of cardiotrophin-1 gene amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis. Acordingly, the cardiotrophin-1 polypeptide encoded by the amplified gene is believed to be a useful target for the diagnosis and/or treatment (including prevention) of certain cancers, and may act as a predictor of the prognosis of tumor treatment.

Abstract: A member of the guanylate-binding protein family, designated GBP-4, is provided. Also provided are isolated nucleic acid encoding GBP-4, vectors and host cells containing such nucleic acid molecule, and a method for producing the GBP-4 recombinantly.

Abstract: DNAs are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.

Abstract: Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.

Abstract: Isolated CT-1, isolated DNA encoding CT-1, and recombinant or synthetic methods of preparing CT-1 are disclosed. CT-1 is shown to bind to and activate the receptor, LIFR&bgr;. These CT-1 molecules are shown to influence hypertrophic activity, neurological activity, and other activities associated with receptor LIFR&bgr;. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, neurological disorders, and other disorders associated with the LIFR&bgr;.

Abstract: A member of the guanylate-binding protein family, designated GBP-4, is provided. Also provided are isolated nucleic acid encoding GBP-4, vectors and host cells containing such nucleic acid molecule, and a method for producing the GBP-4 recombinantly.

Abstract: Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.

Abstract: A method for producing tissue plasminogen activator (t-PA) in eukaryotic host cells is disclosed. Enhanced levels of t-PA production are obtained by co-amplification of the t-PA gene through treatment of cultures transformed with mutant or wild-type DHFR with methotrexate.